Pancreatic Cancer Research

ResearcherAnhui Medical UniversityNo recent work listed

Qiang Huang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0731-3176; OpenAlex author ID A5100698197. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
12
Papers, trials and grants by year

2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: none · 2023: 1 paper

Papers 8

  1. Retraction Note: The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine. Last author DOI 10.1038/s41598-023-48298-9↗
  2. Overexpression of the SMYD3 Promotes Proliferation, Migration, and Invasion of Pancreatic Cancer. First author DOI 10.1007/s10620-019-05797-y↗
  3. Overexpression of circRNA chr7:154954255-154998784+ in cancer-associated pancreatic stellate cells promotes the growth and metastasis of pancreatic cancer by t… Last author PMID 33042405↗
  4. Circular RNA ciRS-7 promotes the proliferation and metastasis of pancreatic cancer by regulating miR-7-mediated EGFR/STAT3 signaling pathway. Last author DOI 10.1016/j.hbpd.2019.03.003↗
  5. The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine. Last author DOI 10.1038/s41598-018-26496-0↗
  6. Expression of Coiled-Coil Domain Containing 34 (CCDC34) and its Prognostic Significance in Pancreatic Adenocarcinoma. Last author DOI 10.12659/msm.907951↗
  7. High-Level Expression and Prognostic Significance of Matrix Metalloprotease-19 and Matrix Metalloprotease-20 in Human Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000569↗
  8. Gemcitabine inhibits immune escape of pancreatic cancer by down regulating the soluble ULBP2 protein. Last author DOI 10.18632/oncotarget.11780↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiansheng Lin · 3 shared papers, 2016–2023 · strength 0.35
  2. Fang Xie · 3 shared papers, 2016–2023 · strength 0.35
  3. Zhen Liu · 2 shared papers, 2018–2023 · strength 0.28
  4. Chenglin Zhu · 1 shared paper, 2020 · strength 0.24
  5. Feng Shao · 2 shared papers, 2017–2020 · strength 0.23
  6. Wei Qi · 1 shared paper, 2017 · strength 0.12
  7. Fubao Liu · 1 shared paper, 2019 · strength 0.10
  8. Lei Liu · 1 shared paper, 2019 · strength 0.10
  9. Chong-Yang Cai · 1 shared paper, 2016 · strength 0.08
  10. Yang Feng Wu · 1 shared paper, 2016 · strength 0.08
  11. Lulu Zhai · 1 shared paper, 2016 · strength 0.08
  12. Zhi‐Gang Tang · 1 shared paper, 2016 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.